A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of WJB001 Capsules in Dose Escalation, Dose Expansion, and Efficacy Expansion in Patients With Advanced Solid Tumors
Latest Information Update: 21 Apr 2026
At a glance
- Drugs WJB 001 (Primary)
- Indications Carcinoma; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wigen Biomedicine
Most Recent Events
- 01 Apr 2026 Planned End Date changed from 23 May 2026 to 23 May 2027.
- 01 Apr 2026 Planned primary completion date changed from 8 Apr 2026 to 8 Aug 2026.
- 08 May 2023 Status changed from not yet recruiting to recruiting.